(Q51321569)

English

Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial.

scientific article published on 19 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

0 references

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

Hertzel C. Gerstein

10

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

author name string

Z Punthakee

1

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

N Alméras

2

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

J-P Després

3

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

G R Dagenais

4

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

S S Anand

5

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

D L Hunt

6

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

A M Sharma

7

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

H Jung

8

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

S Yusuf

9

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

publication date

19 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

Diabetic Medicine

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

31

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

9

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

1086-1092

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Obesity and diabetes: lipids, 'nowhere to run to'.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Liver histology abnormalities in the morbidly obese

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Protocol for measurement of liver fat by computed tomography.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Diet/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Visceral and central abdominal fat and anthropometry in relation to diabetes in Asian Indians

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Thiazolidinediones and the liver in humans

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Thiazolidinediones: metabolic actions in vitro

1 reference

https://api.crossref.org/works/10.1111%2FDME.12512

21 January 2018

Identifiers

10.1111/DME.12512

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24890138

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51321569&oldid=1512251481"